Richardson Bruce, Sawalha Amr H, Ray Donna, Yung Raymond
University of Michigan and the Ann Arbor Veteran's Affairs Hospital, Ann Arbor, MI, USA.
Methods Mol Biol. 2012;900:169-80. doi: 10.1007/978-1-60761-720-4_8.
CD4+ T cell DNA hypomethylation may contribute to the development of drug induced and idiopathic human lupus. Inhibiting DNA methylation in mature CD4+ T cells causes MHC-specific autoreactivity in vitro. The lupus-inducing drugs hydralazine and procainamide also inhibit T cell DNA methylation and induce autoreactivity, and T cells from patients with active lupus have hypomethylated DNA and a similarly autoreactive T cell subset. Further, T cells treated with DNA methylation inhibitors demethylate the same sequences that demethylate in T cells from patients with active lupus. The pathologic significance of the autoreactivity induced by inhibiting T cell DNA methylation has been tested by treating murine T cells in vitro with drugs which modify DNA methylation, then injecting the cells into syngeneic female mice. Mice receiving CD4+ T cells demethylated by a variety of agents including procainamide and hydralazine develop a lupus-like disease. Further, transgenic mice with an inducible T cell DNA methylation defect also develop lupus-like autoimmunity. This chapter describes the protocols for inducing autoreactivity in murine T cells in vitro and for inducing autoimmunity in vivo using an adoptive transfer approach or transgenic animal models.
CD4+ T细胞DNA低甲基化可能促成药物诱导性和特发性人类狼疮的发展。在成熟CD4+ T细胞中抑制DNA甲基化会在体外引发MHC特异性自身反应性。诱发狼疮的药物肼屈嗪和普鲁卡因胺也会抑制T细胞DNA甲基化并诱导自身反应性,而且活动性狼疮患者的T细胞具有低甲基化DNA以及类似的自身反应性T细胞亚群。此外,用DNA甲基化抑制剂处理的T细胞会使与活动性狼疮患者T细胞中发生去甲基化的相同序列去甲基化。通过体外使用改变DNA甲基化的药物处理小鼠T细胞,然后将这些细胞注射到同基因雌性小鼠体内,已对抑制T细胞DNA甲基化所诱导的自身反应性的病理意义进行了测试。接受经包括普鲁卡因胺和肼屈嗪在内的多种试剂去甲基化的CD4+ T细胞的小鼠会患上狼疮样疾病。此外,具有可诱导性T细胞DNA甲基化缺陷的转基因小鼠也会发展出狼疮样自身免疫。本章介绍了在体外诱导小鼠T细胞自身反应性以及使用过继转移方法或转基因动物模型在体内诱导自身免疫的实验方案。